SCHEMBL2436438

SCHEMBL2436438

Fc1ccc(-c2ccc(Br)o2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.52
ALDH1A1 P00352 5/20 0.52
LMNA P02545 4/20 0.52
MAPK13 O15264 1/20 0.48
GCGR P47871 1/20 0.48
MAPK12 P53778 1/20 0.48
MAPK11 Q15759 1/20 0.48
MAPK14 Q16539 1/20 0.48
SLC9A1 P19634 1/20 0.42
NPC1 O15118 6/20 0.41
RAB9A P51151 6/20 0.41
GABRP O00591 2/20 0.41
GABRD O14764 2/20 0.41
GABRA1 P14867 2/20 0.41
GABRB1 P18505 2/20 0.41
GABRG2 P18507 2/20 0.41
GABRB3 P28472 2/20 0.41
GABRA5 P31644 2/20 0.41
GABRA3 P34903 2/20 0.41
GABRA2 P47869 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL398237 0.88 NPC1 (0.47) KDM4EALDH1A1LMNANPC1RAB9A
SCHEMBL12230559 0.76 ALDH1A1 (0.62) KDM4EALDH1A1NPC1RAB9ANQO2
SCHEMBL11983825 0.74 NPC1 (0.46) KDM4EALDH1A1LMNANPC1RAB9A
SCHEMBL15922168 0.73 NPC1 (0.61) KDM4EALDH1A1LMNAMAPK13GCGR
SCHEMBL5539593 0.73 KDM4E (0.52) KDM4EALDH1A1LMNASLC9A1NPC1
SCHEMBL5539598 0.73 GSK3B (0.57) KDM4EALDH1A1LMNASLC9A1NPC1
SCHEMBL24670424 0.72 HRH3 (0.50) KDM4EALDH1A1LMNANPC1RAB9A
SCHEMBL3506668 0.72 F2 (0.45) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL13167116 0.72 NPC1 (0.37) KDM4EALDH1A1LMNAMAPK13GCGR
SCHEMBL15827302 0.72 NPC1 (0.45) KDM4EALDH1A1LMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2545050-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C Bristol-Myers Squibb Company (US) 2013-01-16 EP disclosed
WO-2011112186-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2011-09-15 WO disclosed